Discover more insights into Pd L1 Antibodies

Keywords frequently search together with Pd L1 Antibodies

Narrow sentence examples with built-in keyword filters

Pd L1 Antibodies sentence examples within cell lung cancer



Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models



Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data.


More Pd L1 Antibodies sentence examples
10.3389/fonc.2021.658690

Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma


More Pd L1 Antibodies sentence examples
10.20944/PREPRINTS202103.0777.V1

Prediction of Response to Atezolizumab Plus Nab-Paclitaxel in Unresectable Locally Advanced Triple Negative Breast Cancer (TNBC): the ClinicalUsefulness of PD-L1 mRNA Expression in Plasma-Derived Exosomes


More Pd L1 Antibodies sentence examples
10.1200/JCO.2021.39.15_SUPPL.E21173

An investigation on biomarkers of hyperprogressive disease after PD-1/PDL-1 therapies in Chinese non-small cell lung cancer patients.


More Pd L1 Antibodies sentence examples
10.3389/fimmu.2021.686879

Diagnostic and Therapeutic Approach in a Metastatic Vaginal Adenocarcinoma: A Case Report



Network Meta-analysis Comparing Efficacy, Safety and Tolerability of Anti-PD-1/PD-L1 Antibodies in Solid Cancers


More Pd L1 Antibodies sentence examples
10.1038/s41388-021-01689-6

HuR up-regulates cell surface PD-L1 via stabilizing CMTM6 transcript in cancer


More Pd L1 Antibodies sentence examples
10.1016/j.pulmoe.2021.07.005

Encephalitis in non-small-cell lung cancer.


More Pd L1 Antibodies sentence examples
10.1016/j.celrep.2021.109181

PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR


More Pd L1 Antibodies sentence examples
10.1016/j.nucmedbio.2021.05.004

Non-invasive immunoPET imaging of PD-L1 using anti-PD-L1-B11 in breast cancer and melanoma tumor model.


More Pd L1 Antibodies sentence examples
10.1158/1535-7163.MCT-20-0944

Novel TGFβ Inhibitors Ameliorate Oral Squamous Cell Carcinoma Progression and Improve the Antitumor Immune Response of Anti–PD-L1 Immunotherapy


More Pd L1 Antibodies sentence examples
10.1080/2162402X.2021.1958590

Avelumab internalization by human circulating immune cells is mediated by both Fc gamma receptor and PD-L1 binding


More Pd L1 Antibodies sentence examples
10.1200/JCO.2021.39.15_SUPPL.2595

Phase II trial of MEDI0457 and durvalumab for patients with recurrent/metastatic HPV-associated cancers.


More Pd L1 Antibodies sentence examples
10.1186/s12885-021-08859-5

Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment


More Pd L1 Antibodies sentence examples
10.3389/fphar.2021.742862

Immune Checkpoint Inhibitors Regulate K+ Channel Activity in Cytotoxic T Lymphocytes of Head and Neck Cancer Patients


More Pd L1 Antibodies sentence examples
10.1038/s43018-021-00232-6

Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression



PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a 177Lu-labeled αPD-L1 antibody


More Pd L1 Antibodies sentence examples
10.1007/s11864-020-00808-x

Refining Immuno-Oncology Approaches in Metastatic Prostate Cancer: Transcending Current Limitations



Biomimetic nanoemulsion for synergistic photodynamic-immunotherapy against hypoxic breast tumor.


More Pd L1 Antibodies sentence examples
10.3390/cancers13164036

Hypothalamic–Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies


More Pd L1 Antibodies sentence examples
10.3389/fonc.2021.752725

Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials


More Pd L1 Antibodies sentence examples
10.1051/E3SCONF/202126702026

Innovative immunotherapy targeting at PD-1/PD-L1 signaling pathway: mechanism, efficacy and safety analysis of monotherapy and combination therapies in non-small cell lung cancer (NSCLC) treatment



PARP inhibitors and immunotherapy in ovarian and endometrial cancers.


More Pd L1 Antibodies sentence examples
10.1016/j.therap.2021.06.005

[Current landscape of biomarker development for immune checkpoint inhibitors targeting PD-1/PD-L1 pathway in oncology].


More Pd L1 Antibodies sentence examples
10.1126/scitranslmed.abd1616

Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models


More Pd L1 Antibodies sentence examples
10.1158/1538-7445.SABCS20-SP33

Abstract SP033: How and when to use immunotherapy and related toxicities



Virtual Evolution of HVEM Segment for Checkpoint Inhibitor Discovery



Knockdown of Chitinase 3-Like-1 Inhibits Cell Proliferation, Promotes Apoptosis, and Enhances Effect of Anti-Programmed Death Ligand 1 (PD-L1) in Diffuse Large B Cell Lymphoma Cells


More Pd L1 Antibodies sentence examples
10.1016/j.ymthe.2021.05.017

Photodynamic Therapy Synergize with PD-L1 Checkpoint Blockade for Immunotherapy of Colorectal Cancer by Multifunctional Nanoparticle.


More Pd L1 Antibodies sentence examples
10.1038/s41598-021-98113-6

Weekly Paclitaxel given concurrently with Durvalumab has a favorable safety profile in triple-negative metastatic breast cancer


More Pd L1 Antibodies sentence examples
10.1200/JCO.2021.39.15_SUPPL.9055

SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, for advanced NSCLC with EGFR mutations: Data from a multicenter phase 1 study.


More Pd L1 Antibodies sentence examples
10.1038/s41598-021-97250-2

PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection



PD-L1 aptamer isolation via Modular-SELEX and its applications in cancer cell detection and tumor tissue section imaging.


More Pd L1 Antibodies sentence examples
10.3390/cancers13020164

PD-L1/PD-1 Axis in Multiple Myeloma Microenvironment and a Possible Link with CD38-Mediated Immune-Suppression



Detection of PD-L1 Expression in Temozolomide-Resistant Glioblastoma by Using PD-L1 Antibodies Conjugated with Lipid‑Coated Superparamagnetic Iron Oxide


More Pd L1 Antibodies sentence examples
10.1200/jco.2021.39.15_suppl.e20574

Efficacy and safety of PD-1/PD-L1 antibody combined with chemotherapy as second-line or third-line treatment for metastatic small cell lung cancer.


More Pd L1 Antibodies sentence examples
10.31557/APJCP.2021.22.6.1943

NFATc1 is Suppressed in Tumor Microenvironment of Hodgkin Lymphoma


More Pd L1 Antibodies sentence examples
10.1016/j.oraloncology.2020.105127

Targeting the PD-1/ PD-L1 interaction in nasopharyngeal carcinoma.



RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma.



A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with 68Ga-labeled PD-L1 targeted nanobody


More Pd L1 Antibodies sentence examples
10.1158/1078-0432.CCR-21-0261

Safety and antitumor activity of α-PD-L1 antibody as monotherapy or in combination with α-TIM-3 antibody in patients with microsatellite instability-high/mismatch repair-deficient tumors.


More Pd L1 Antibodies sentence examples
10.1172/jci.insight.131458

PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer


More Pd L1 Antibodies sentence examples
10.1200/JCO.2021.39.15_SUPPL.E14026

Combination olaparib and durvalumab for patients with recurrent IDH-mutated gliomas.


More Pd L1 Antibodies sentence examples
10.3390/cancers13061256

Anti-Tumor Efficacy of PD-L1 Targeted Alpha-Particle Therapy in a Human Melanoma Xenograft Model



Mechanisms of PD-L1 Regulation in Malignant and Virus-Infected Cells



Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data.


More Pd L1 Antibodies sentence examples
10.1200/JCO.2021.39.15_SUPPL.TPS9128

AdvanTIG-302: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC).


More Pd L1 Antibodies sentence examples
10.1038/s41598-021-81666-x

Clinical pattern of failure after a durable response to immune check inhibitors in non-small cell lung cancer patients



Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials.


More Pd L1 Antibodies sentence examples
10.1016/j.clim.2021.108742

PD-1 signaling pathway in sepsis: Does it have a future?



Expression of p53 Protein Associates with Anti-PD-L1 Treatment Response on Human-Derived Xenograft Model of GATA3/CR5/6-Negative Recurrent Nonmuscular Invasive Bladder Urothelial Carcinoma


More Pd L1 Antibodies sentence examples
10.1158/1538-7445.AM2021-LB040

Abstract LB040: Targeting CD38 and PD-1 with isatuximab (Isa) plus cemiplimab (Cemi) in patients (pts) with advanced malignancies: Results from a Phase 1/2 open-label, multicenter study


More Pd L1 Antibodies sentence examples
10.1038/s41571-021-00473-5

PD-L1 as a biomarker of response to immune-checkpoint inhibitors


More Pd L1 Antibodies sentence examples
10.1016/j.jmoldx.2021.07.026

Molecular Testing in Breast Cancer: Current Status and Future Directions.



Evaluating PD-L1 in Head & Neck Squamous Cell Carcinoma: concordance between 22C3 PharmaDx and SP263 assays on whole sections from a multicenter study.


More Pd L1 Antibodies sentence examples
10.3390/cancers13051065

Perspective of Immune Checkpoint Inhibitors in Thymic Carcinoma


More Pd L1 Antibodies sentence examples
10.1101/2021.10.21.464997

SiglecFhigh neutrophils in lung tumor tissues suppress local CD8 T cell responses and limit the efficacy of anti PD-L1 antibodies


More Pd L1 Antibodies sentence examples
10.1186/s12943-020-01304-4

A comparability study of natural and deglycosylated PD-L1 levels in lung cancer: evidence from immunohistochemical analysis


More Pd L1 Antibodies sentence examples
10.1038/s41571-021-00520-1

Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC



Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors


More Pd L1 Antibodies sentence examples
10.1080/2162402X.2020.1860482

T cells expanded from renal cell carcinoma display tumor-specific CD137 expression but lack significant IFN-γ, TNF-α or IL-2 production


More Pd L1 Antibodies sentence examples
10.1200/JCO.2021.39.15_SUPPL.TPS2671

Trials in progress: A phase 1, open-label, dose-escalation, pharmacokinetic, safety and tolerability study of the selective TAM kinase inhibitor PF-07265807 in patients with advanced or metastatic solid tumors.


More Pd L1 Antibodies sentence examples
10.2174/1574893616666210707101516

Inhibitory Effect of PD-1/PD-L1 and Blockade Immunotherapy in Leukemia.


More Pd L1 Antibodies sentence examples
10.1158/1535-7163.MCT-21-0031

Anti-VEGF antibody protects against alveolar exudate leakage caused by vascular hyperpermeability, resulting in mitigation of pneumonitis induced by immunotherapy.


More Pd L1 Antibodies sentence examples
10.1038/s41598-021-93113-y

Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab


More Pd L1 Antibodies sentence examples
10.1038/s41419-021-03568-0

Immunotherapy for recurrent glioblastoma: practical insights and challenging prospects



Inhibition of Transforming Growth Factor Beta and Immune Checkpoints Induces a Distinctively Distributed, Severe Bullous Pemphigoid.


More Pd L1 Antibodies sentence examples
10.1158/0008-5472.CAN-20-2370

MEK Inhibition Remodels the Immune Landscape of Mutant KRAS Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors


More Pd L1 Antibodies sentence examples
10.1200/JCO.2021.39.15_SUPPL.4096

Regomune: A phase II study of regorafenib + avelumab in solid tumors—Results of the biliary tract cancer (BTC) cohort.


More Pd L1 Antibodies sentence examples
10.1158/1538-7445.AM2021-LB135

Abstract LB135: Simultaneous costimulatory T-cell engagement and checkpoint inhibition by PRS-344/S095012, a PD-L1/4-1BB bispecific compound for tumor localized activation of the immune system


More Pd L1 Antibodies sentence examples
10.1016/j.oraloncology.2021.105472

TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells.



Analytical Concordance of PD-L1 Assays Utilizing Antibodies From FDA-Approved Diagnostics in Advanced Cancers: A Systematic Literature Review


More Pd L1 Antibodies sentence examples
10.1200/JCO.2021.39.15_SUPPL.E15560

A single-arm study on the efficacy and safety of regorafenib plus sintilimab as salvage-line treatments in non-MSI-H metastatic colorectal cancer.



Expression and Prognostic Value of the Immune Checkpoints Galectin-9 and PD-L1 in Glioblastomas.


More Pd L1 Antibodies sentence examples
10.21203/RS.3.RS-218700/V1